The Week Ahead in Biotech (Nov. 7–Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs, and More

Despite the no-treatment strategy offered by health agencies, internist and epidemiologist Dr. Peter McCullough couldn’t just stand by and do nothing. Billion Photos/Shutterstock

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.

What was good news for Pfizer, Inc. turned out to be negative for several others engaged in COVID-19 vaccine and treatment research. Pfizer announced Friday its oral COVID-19 pill Paxlovid reduced the risk of COVID-19-related hospitalization or death by 89 percent.